Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials

JAMA - Journal of the American Medical Association

Volumn 319, Issue 2, 2018, Pages 130-142

  Atri, Alireza ^a   Frölich, Lutz ^b   Ballard, Clive ^c   Tariot, Pierre N ^d   Molinuevo, José Luis ^e,f   Boneva, Neli ^g   Windfeld, Kristian ^g,h   Raket, Lars L ^g   Cummings, Jeffrey L ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^d BANNER ALZHEIMER S INSTITUTE   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f Clinical Research Program   (Spain)

^g H LUNDBECK A S   (Denmark)

^h Genmab   (Denmark)

ⁱ Lou Ruvo Center for Brain Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA GLUTAMYLTRANSFERASE; IDALOPIRDINE; PLACEBO; RIVASTIGMINE; (2-(6-FLUORO-1H-INDOL-3-YL)-ETHYL)-(3-(2,2,3,3-TETRAFLUOROPROPOXY)BENZYL)AMINE; BENZYLAMINE DERIVATIVE; INDAN DERIVATIVE; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ACTIVITY OF DAILY LIVING ASSESSMENT; ADULT; ADVERSE EVENT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ANXIETY; ASPARTATE AMINOTRANSFERASE LEVEL; BODY WEIGHT LOSS; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG OVERDOSE; FALLING; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; TREATMENT FAILURE; VERY ELDERLY;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BENZYLAMINES; CHOLINESTERASE INHIBITORS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GALANTAMINE; HUMANS; INDANS; INDOLES; MALE; MIDDLE AGED; PIPERIDINES; RIVASTIGMINE; SEROTONIN ANTAGONISTS; TREATMENT FAILURE;

EID: 85040590159     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.20373     Document Type: Conference Paper

References (26)

1. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016; 12(4):459-509.
2. Schneider LS. A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer’s disease. Dialogues Clin Neurosci. 2000;2(2):111-128.
3. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32 (7):1234-1251.
4. Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol. 2012;99(1):15-41.
5. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics. 2008;5(3):458-469.
6. Ramírez MJ. 5-HT6 receptors and Alzheimer’s disease. Alzheimers Res Ther. 2013;5(2):15.
7. Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer’s disease: a new therapeutic target? CNS Drugs. 2011;25(9):765-781.
8. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Curr Alzheimer Res. 2010;7(5): 374-385.
9. Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011;26(5):536-544.
10. Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13(11):1092-1099.
11. Maher-Edwards G, Watson C, Ascher J, et al. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer’s disease. Alzheimers Dement. 2015;1(1):23-36.
12. US Department of Health and Human Services; US Food and Drug Administration. ICH harmonised tripartite guideline E6: guideline for good clinical practice. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation /guidances/ucm073122.pdf. Accessed October 31, 2016.
13. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-944.
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141(11):1356-1364.
16. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.
17. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study–Clinical Global Impression of Change: the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2): S22-S32.
18. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
19. US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. https://www.fda.gov/downloads/Guidances/UCM174090.pdf. Accessed December 7, 2017.
20. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
21. Ayele BT, Lipkovich I, Molenberghs G, Mallinckrodt CH. A multiple-imputation-based approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials. J Biopharm Stat. 2014;24(2):211-228.
22. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med. 2009;28(4): 586-604.
23. US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Guidance for industry: exposure-response relationships—study design, data analysis, and regulatory applications. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation /guidances/ucm072109.pdf. Accessed December 7, 2017.
24. Schmidt E, Kuwabara H, Areberg J, et al. A clinical positron emission tomography (PET) study investigating occupancy at the 5-HT6 receptor after multiple oral doses of LU AE58054 to healthy men. Alzheimers Dement. 2014;10(4):P925.
25. Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006;7:36.
26. Axovant Sciences Inc. Axovant announces negative topline results of intepirdine phase 3 MINDSET trial in Alzheimer's disease. http://investors.axovant.com/news-releases/news-release-details/axovant-announces -negative-topline-results-intepirdine-phase-3. Accessed November 28, 2017.